AU732794B2 - Method for induction of apoptotic cell death in malignant cells, through reduction of the Rb to apoptosis inducing proteins ratio - Google Patents

Method for induction of apoptotic cell death in malignant cells, through reduction of the Rb to apoptosis inducing proteins ratio Download PDF

Info

Publication number
AU732794B2
AU732794B2 AU59831/98A AU5983198A AU732794B2 AU 732794 B2 AU732794 B2 AU 732794B2 AU 59831/98 A AU59831/98 A AU 59831/98A AU 5983198 A AU5983198 A AU 5983198A AU 732794 B2 AU732794 B2 AU 732794B2
Authority
AU
Australia
Prior art keywords
cells
prb
protein
gene
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU59831/98A
Other languages
English (en)
Other versions
AU5983198A (en
Inventor
Jiri Bartek
Jiri Lukas
Volker Sandig
Michael Strauss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
HepaVec AG fur Gentherapie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HepaVec AG fur Gentherapie filed Critical HepaVec AG fur Gentherapie
Publication of AU5983198A publication Critical patent/AU5983198A/en
Application granted granted Critical
Publication of AU732794B2 publication Critical patent/AU732794B2/en
Assigned to DEVELOGEN AKTIENGESELLSCHAFT FUR ENTWICKLUNGSBIOLOGISCHE FORSCHUNG reassignment DEVELOGEN AKTIENGESELLSCHAFT FUR ENTWICKLUNGSBIOLOGISCHE FORSCHUNG Amend patent request/document other than specification (104) Assignors: HEPAVEC AKTIENGESELLSCHAFT FUR GENTHERAPIE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU59831/98A 1997-02-20 1998-02-20 Method for induction of apoptotic cell death in malignant cells, through reduction of the Rb to apoptosis inducing proteins ratio Ceased AU732794B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK18397 1997-02-20
DK183/97 1997-02-20
US91922697A 1997-08-28 1997-08-28
US08/919226 1997-08-28
PCT/DK1998/000068 WO1998037190A1 (en) 1997-02-20 1998-02-20 Method for induction of apoptotic cell death in malignant cells, through reduction of the rb to apoptosis inducing proteins ratio

Publications (2)

Publication Number Publication Date
AU5983198A AU5983198A (en) 1998-09-09
AU732794B2 true AU732794B2 (en) 2001-05-03

Family

ID=26063484

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59831/98A Ceased AU732794B2 (en) 1997-02-20 1998-02-20 Method for induction of apoptotic cell death in malignant cells, through reduction of the Rb to apoptosis inducing proteins ratio

Country Status (8)

Country Link
EP (1) EP1007662A1 (ja)
JP (1) JP2001524812A (ja)
CN (1) CN1248290A (ja)
AU (1) AU732794B2 (ja)
CA (1) CA2283090A1 (ja)
DE (1) DE1007662T1 (ja)
ES (1) ES2150891T1 (ja)
WO (1) WO1998037190A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794771B1 (fr) * 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
KR101968637B1 (ko) 2012-12-07 2019-04-12 삼성전자주식회사 유연성 반도체소자 및 그 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539130A1 (de) * 1995-02-28 1996-08-29 Max Planck Gesellschaft Mittel zur Therapie von Tumoren und anderen Hyperplasien

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015245A1 (en) * 1994-11-11 1996-05-23 Arch Development Corporation A process of inhibiting non-neoplastic pathological cell proliferation
US6033847A (en) * 1995-02-06 2000-03-07 St. Jude Children's Research Hospital InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof
AU724324B2 (en) * 1995-07-17 2000-09-14 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539130A1 (de) * 1995-02-28 1996-08-29 Max Planck Gesellschaft Mittel zur Therapie von Tumoren und anderen Hyperplasien

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EASTHAM JA ET AL. CANCER RES. 1995 15(22):5151-5155 *
KATAOKA ET AL. CANCER GENE THER. 1996.3(6):540 *

Also Published As

Publication number Publication date
WO1998037190A1 (en) 1998-08-27
ES2150891T1 (es) 2000-12-16
JP2001524812A (ja) 2001-12-04
EP1007662A1 (en) 2000-06-14
AU5983198A (en) 1998-09-09
CN1248290A (zh) 2000-03-22
DE1007662T1 (de) 2001-04-19
CA2283090A1 (en) 1998-08-27

Similar Documents

Publication Publication Date Title
KR100379174B1 (ko) DNA손상제및p53을포함하는조성물
Sandig et al. Adenovirally transferred p16 INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death
Madireddi et al. Mda-7, a novel melanoma differentiation associated gene with promise for cancer gene therapy
US6830749B2 (en) Recombinant P53 adenovirus methods and compositions
Fulci et al. p53 and brain tumors: from gene mutations to gene therapy
KR100747646B1 (ko) 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
Steiner et al. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence
US8012925B2 (en) Agent for inducing apoptosis comprising MSX1 or a gene encoding the same as an active ingredient
RU2192431C2 (ru) Синтетический мутантный ген rb (варианты), синтетический мутантный ген p53, плазмида (варианты), мутантный белок (варианты), способ ингибирования клеточной пролиферации (варианты), способ индуцирования апоптоза
AU732794B2 (en) Method for induction of apoptotic cell death in malignant cells, through reduction of the Rb to apoptosis inducing proteins ratio
Randrianarison et al. BRCA1 carries tumor suppressor activity distinct from that of p53 and p21
US7163925B1 (en) p16 expression constructs and their application in cancer therapy
US8187586B2 (en) Methods of inducing apoptosis in hyperproliferative cells
RU2252255C2 (ru) Вектор доставки генов, способный индуцировать апоптоз в клетке
Roth et al. Gene replacement strategies for lung cancer
JPH11506325A (ja) Δｐ６２、その変異体、核酸配列及びこれらの使用
Cerrato Mechanisms of Ad-p53 induced apoptosis in human malignant glioma
Canman Michael B. Kastan The Johns Hopkins Oncology Center Baltimore, Maryland 21205

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: DEVELOGEN AKTIENGESELLSCHAFT FUR ENTWICKLUNGSBIOLO

Free format text: FORMER NAME: HEPAVEC AKTIENGESELLSCHAFT FUR GENTHERAPIE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired